Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin 2.5 mg BID plus metformin versus placebo plus metformin in type 2 diabetes mellitus with inadequate glycemic control
2009-010224-25Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin 2.5 mg BID + metformin with Placebo BID + metformin (2 arms). Primary endpoint: Change in HbA1c from baseline to Week 12. Started May 2009; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-010224-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010224-25.